Recently, the US Food and Drug Administration (FDA) officially awarded SurVaxM vaccine "orphan drug" qualification. The vaccine is used for the treatment of glioblastoma, which was developed by Michael Ciesielski-associate professor of the Neurosurgery and Robert Fenstermaker-director of neurosurgery, both in Roswell Park Cancer Institute.
SurVaxM vaccine is mainly used to inhibit the expression of survivin protein. The survivin protein is a member of the family of apoptotic proteins, with a molecular weight of 16.5 kDa, which could inhibit apoptosis, promote cell proliferation, and induce or enhance angiogenesis. Survivin existed in many types of malignancies, such as lung cancer, rectal cancer, liver cancer and gastric cancer, but rarely expressed in normal human tissue. This ubiquitous expression suggested that survivin might have the anti-tumor effect by being antagonized.
In bladder transitional cell carcinoma, survivin has become a biomarker for cancer diagnosis, prognosis and predicting bladder or systemic response. In addition, in the preclinical bladder tumor model, inhibiting the survivin expression and / or function can affect tumor cell proliferation and significantly induce spontaneous or chemotherapy-induced apoptosis.
The products, including survivin antibody, survivin ELISA kit, anti-survivin ELISA kit, survivin CLIA kit and anti-survivin CLIA kit, have independently been developed and produced by EIAab Technology Co. Ltd.
Please enter into www.eiaab.net. for details. Welcome to consult and order!